ArticleNature2022
A vaccine targeting resistant tumours by dual T cell plus NK cell attack.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 2 pooled it
11.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 2 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Targeting DNA damage response to enhance cancer immunotherapy efficacy: molecular mechanisms and clinical advances.Medical oncology (Northwood, London, England) · 2025Pooled it
- Advances on cancer vaccine trials registered in China and the USA in 2014-2024.Frontiers in oncology · 2025Pooled it
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- Designing lysate-based hydrogels for on-demand therapy.Journal of pharmaceutical analysis · 2026Review
- Safe and Localized Lentiviral Gene Delivery via Injectable Mesoporous Scaffolds for Potent Antitumor Immunity.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Targeting the MICA/B-NKG2D axis in cancer: from molecular structure to immunotherapeutic strategies-a narrative review.Translational cancer research · 2026Review
- Disrupting USP14-mediated PARP1 dynamics reinstates MIC-A/B-driven antigen-independent CD8Science advances · 2026Article
- HBx Promotes Liver Cancer Cells to Escape NK-92 Cell Attack by Mediating ADAM10 to Enzyme Cut MICA/B Shedding From Cancer Cell Membrane.Journal of cellular and molecular medicine · 2026Article
- Alpha-Fetoprotein Stimulates Cleavage of Membranal MICA/B on Liver Cancer Cell Lead to Escape Immune Surveillance of Natural Killer Cells.Journal of cellular and molecular medicine · 2026Article
- Pipe dream to pipeline: Journey of cancer vaccines and the road ahead.Cell reports. Medicine · 2026Review
- Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses.Nature biomedical engineering · 2026Article
- CD300ld blockade overcomes PMN-MDSC-mediated vaccine resistance in advanced tumors.Journal for immunotherapy of cancer · 2026Article
- Targeting NKG2D/NKG2DL axis in cancer immunotherapy: mechanisms and therapeutic applications.Journal of translational medicine · 2026Review
- A Novel MICB-Targeting CAR-NK Cells for the Treatment of Pancreatic Cancer.International journal of molecular sciences · 2026Article
- Advances inFrontiers in immunology · 2026Article
- Insights into ectodomain shedding as a novel target in natural killer cell-based immunotherapy for cancer.Frontiers in immunology · 2026Review
- A fully human IgG1 antibody targeting MICA α1 domain inhibits interaction with NKG2D and activates immune effector functions against MICA-expressing cells.Frontiers in immunology · 2026Article
- Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026Review
- Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.International journal of biological sciences · 2026Review
- Association Between Amino Acid Polymorphisms in MICA and MICA-NKG2D Interaction Affinity: Implications and Significance for Tumor Immunity.Biomolecules · 2025Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 5 institutions in 2 countries.
Soumya BadrinathDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Maxence O Dellacherie *John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.
Aileen Li *John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.
Shiwei Zheng *Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Xixi ZhangDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Miguel SobralJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.
Jason W PyrdolDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kathryn L SmithDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9799-036X
Yuheng LuDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Sabrina HaagDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hamza IjazWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Fawn Connor-StroudYerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Tsuneyasu KaishoDepartment of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.ORCID http://orcid.org/0000-0003-2616-1665
Glenn DranoffDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Guo-Cheng YuanDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2283-4714
David J MooneyJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6299-1194
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. Kai_Wucherpfennig@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-1829-302X
Harvard University · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USEmory University · USWakayama Medical University · JP
Funding
Transcriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 2013 to 2026
$25.3MUnderstanding and Overcoming T cell Immunosuppression in GlioblastomaP01CA236749 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI E. Antonio Chiocca, DAVID A REARDON · 2020 to 2026
$19.5MTherapeutic Targeting of Immune Evasion from the MICA - NKG2D PathwayR01CA238039 · NCI · DANA-FARBER CANCER INST · PI Kai W Wucherpfennig · 2019 to 2026
$4.2MTargeting of a Major Immune Evasion Pathway in Triple-negative Breast CancerR01CA251599 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2020 to 2024
$2.4MRegulators of Cancer Immunotherapy ResponseR01CA234018 · NCI · DANA-FARBER CANCER INST · PI BROWN, MYLES A · 2019 to 2022
$2.3MBiomaterial Cancer Vaccines that Generate Patient-Specific Antigen In SituR01CA223255 · NCI · HARVARD UNIVERSITY · PI MOONEY, DAVID J · 2018 to 2022
$2.1MBig Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0MNCI NIH HHS P01 CA163222NCI NIH HHS P01 CA236749NCI NIH HHS R01 CA223255NCI NIH HHS R01 CA234018NCI NIH HHS R01 CA238039NCI NIH HHS R01 CA251599NIH HHS S10 OD026880
Abstract
Most cancer vaccines target peptide antigens, necessitating personalization owing to the vast inter-individual diversity in major histocompatibility complex (MHC) molecules that present peptides to T cells. Furthermore, tumours frequently escape T cell-mediated immunity through mechanisms that interfere with peptide presentation
Indexed as
Myelodysplastic SyndromesNeoplasmsSkin Diseases, GeneticVaccinesHistocompatibility Antigens Class IHumansKiller Cells, NaturalNK Cell Lectin-Like Receptor Subfamily KHistocompatibility Antigens Class INK Cell Lectin-Like Receptor Subfamily KVaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.